Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Feb 15, 2024; 16(2): 273-286
Published online Feb 15, 2024. doi: 10.4251/wjgo.v16.i2.273
Published online Feb 15, 2024. doi: 10.4251/wjgo.v16.i2.273
Table 4 Immunotherapy drug approved for hepatocellular carcinoma
| Drug target | Drug name | Drug launch time | Listed in China |
| PD-1 | Nivolumab | 2017 | No |
| PD-1 | Pembrolizumab | 2018 | Yes |
| CTLA-4 | Ipilimumab | 2020 | No |
| PD-1 | Tislelizumab | 2021 | Yes |
| PD-1 | Sintilimab | 2021 | Yes |
| PD-1 + CTLA-4 | Tremelimumab + durvalumab | 2022 | No |
- Citation: Pan D, Liu HN, Qu PF, Ma X, Ma LY, Chen XX, Wang YQ, Qin XB, Han ZX. Progress in the treatment of advanced hepatocellular carcinoma with immune combination therapy. World J Gastrointest Oncol 2024; 16(2): 273-286
- URL: https://www.wjgnet.com/1948-5204/full/v16/i2/273.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i2.273